Medicskin Holdings Ltd. (8307) AI Stock Analysis

• Market Cap: HK$63.48M
• Dividend Yield: N/A
• Average Volume (3M): 24.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: -2.91%
• EPS Growth: 55.41%
• Country: HK
• Employees: 29
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.00
• Shares Outstanding: 396,736,000
• 10 Day Avg. Volume: 59,600
• 30 Day Avg. Volume: 24,666
• PEG Ratio: -2.10
• Price to Book (P/B): 17.59
• Price to Sales (P/S): 1.64
• P/FCF Ratio: 8.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: HK$0.14 ▼(-15.29% Downside)

Medicskin Holdings Ltd. faces significant challenges, primarily due to its financial performance and valuation. High leverage and negative profitability are key risks, while technical indicators suggest bearish momentum. Strong cash flow management is a relative strength but insufficient to offset other concerns.

Positive Factors

Cash Flow Management

Efficient cash management supports liquidity and operational stability, providing a buffer against financial challenges and aiding in strategic investments.

Operational Efficiency

Incremental improvements in operational efficiency suggest potential for cost management and operational resilience, which can enhance profitability over time.

Market Reach

Diverse revenue streams through e-commerce and partnerships enhance market reach, providing a stable income base and opportunities for growth in the healthcare sector.

Negative Factors

High Leverage

Significant leverage increases financial risk, potentially limiting flexibility and increasing vulnerability to economic downturns, impacting long-term financial health.

Declining Revenue

A decline in revenue signals potential challenges in market demand or competitive positioning, which could hinder growth and profitability if not addressed.

Profitability Challenges

Decreasing margins indicate rising costs or pricing pressures, which can erode profitability and necessitate strategic adjustments to maintain financial performance.

Medicskin Holdings Ltd. Business Overview & Revenue Model

Company Description

Medicskin Holdings Ltd. (8307) is a leading healthcare company specializing in advanced dermatological and aesthetic solutions. The company operates in the medical and cosmetic sectors, offering a range of products and services designed to enhance skin health and appearance. Medicskin is known for its innovative skincare products, medical devices, and aesthetic treatments, catering to both consumers and healthcare professionals.

How the Company Makes Money

Medicskin Holdings Ltd. generates revenue primarily through the sale of its skincare products and medical devices. The company sells its products directly to consumers via e-commerce platforms and through partnerships with dermatologists and aesthetic clinics. Additionally, Medicskin earns income from providing aesthetic treatment services in its clinics. Key revenue streams include product sales, treatment fees, and potential licensing agreements for proprietary technology. Strategic partnerships with healthcare providers and distributors also enhance its market reach and contribute to overall earnings.

Medicskin Holdings Ltd. Financial Statement Overview

Summary

Medicskin Holdings Ltd. faces profitability challenges with declining revenue and negative net income. High leverage and reduced equity present financial risks, though strong cash flow management offers some resilience.

Income Statement

Medicskin Holdings Ltd. shows a mixed performance in its income statement. The gross profit margin has declined from 80.2% in 2022 to 50.7% in 2025, indicating increased cost pressures. The net profit margin is negative for the past three years, reflecting ongoing challenges in achieving profitability. Revenue has decreased by 8.2% from 2024 to 2025, highlighting a potential concern in growth. Despite these challenges, the company has improved its EBITDA margin from 13.8% in 2023 to 13.9% in 2025, showing some operational efficiency improvements.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 5.44 in 2025, indicating significant leverage which poses a financial risk. Stockholders' equity has decreased substantially over the years, reflecting potential financial instability. The equity ratio has also diminished to 7.3% in 2025, suggesting limited financial cushion. Return on equity is not applicable due to negative net income. These factors collectively suggest a need for careful management of financial leverage and equity to ensure long-term stability.

Cash Flow

The cash flow statement shows resilience with a strong free cash flow to net income ratio, despite negative net income, indicating efficient cash management. Operating cash flow has increased to HKD 9.13 million in 2025, supporting liquidity. However, the free cash flow has shown a marginal decrease from the previous year, and capital expenditures have been managed to support cash flow effectively. Overall, the cash flow position remains a relative strength for Medicskin Holdings Ltd.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.27M	45.11M	49.88M	45.54M	49.15M	41.71M
Gross Profit	18.77M	22.87M	39.39M	36.68M	42.14M	34.40M
EBITDA	6.76M	6.29M	6.78M	6.40M	14.55M	11.62M
Net Income	-1.98M	-3.38M	-3.05M	-3.54M	3.92M	953.00K
Balance Sheet
Total Assets	50.00M	57.44M	40.06M	46.37M	56.67M	58.84M
Cash, Cash Equivalents and Short-Term Investments	25.16M	17.34M	6.93M	6.37M	15.47M	30.33M
Total Debt	19.89M	22.79M	5.76M	11.93M	18.67M	6.42M
Total Liabilities	45.77M	53.25M	32.48M	35.21M	42.49M	38.85M
Stockholders Equity	4.23M	4.20M	10.95M	14.47M	17.43M	23.45M
Cash Flow
Free Cash Flow	9.44M	8.29M	9.12M	946.00K	2.33M	6.84M
Operating Cash Flow	11.42M	9.13M	10.52M	3.25M	4.29M	9.15M
Investing Cash Flow	-2.84M	-191.00K	-1.40M	-5.67M	-1.82M	-1.65M
Financing Cash Flow	-8.26M	1.48M	-7.21M	-6.74M	-17.94M	-21.03M

Medicskin Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8307, the sentiment is Neutral. The current price of 0.17 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.17, and below the 200-day MA of 0.18, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 46.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:8307.

Medicskin Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8161	53 Neutral	HK$25.38M	2.88	125.77%	―	-20.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8357	51 Neutral	HK$63.65M	-8.64	-10.31%	―	-11.68%	-71.01%
2135	50 Neutral	HK$80.22M	-1.16	-51.07%	―	-20.66%	-77.84%
8307	48 Neutral	HK$63.48M	-48.48	-19.93%	―	-2.91%	55.41%
8143	46 Neutral	HK$226.59M	-7.49	-132.60%	―	-30.45%	-734.38%
8437	44 Neutral	HK$21.31M	-0.72	―	―	14.64%	-81.95%